Insider: Guyer Charles Greg EVP, Chief Technical Officer - BIOMARIN PHARMACEUTICAL INC
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 79,953 | 0 | 79,953 |
| Value | $4,437,391.50 | $0.00 | $4,437,391.50 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 03/11/2026 | DDS | 16,486 | Direct | COM | $60.46 | $996,743.56 | 79,953 |
| 03/06/2025 | DDS | 7,034 | Direct | COM | $71.28 | $501,355.38 | 87,655 |
| 11/12/2024 | DDS | 5,278 | Direct | COM | $66.37 | $350,323.56 | 68,909 |
| 08/09/2023 | DDS | 5,360 | Direct | COM | $93.30 | $500,109.44 | 40,041 |
| 08/08/2022 | DDS | 6,205 | Direct | COM | $96.56 | $599,154.80 | 42,168 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2026 Zacks Investment Research